Clinical studies on bacampicillin in the treatment of respiratory tract infections

Akira Watanabe, Kotaro Oizumi, Kiyoshi Konno, Izumi Hayashi

    Research output: Contribution to journalArticlepeer-review


    Clinical investigations were performed on bacampicillin, a new orally well-absorbed semisynthetic penicillin which is high active in vivo due to rapid transformation into ampicillin. Bacampicillin was administered to total 27 cases of respiratory tract infections, at daily dose of 1.0 g for 28 days to 8 cases of bronchitis, 18 cases of pneumonia and a daily dose of 1.5 g for 14 days to a case of pneumonia. Clinical response of bacampicillin was excellent in 15 cases, good in 8 cases and fairly effective in 4 cases. Side effects with bacampicillin were observed in 3 cases consisting of one skin eruption, one eosinophilia and one elevation of serum transaminase. These turned to normal by discontinuing the drug.

    Original languageEnglish
    Pages (from-to)907-912
    Number of pages6
    Issue number6
    Publication statusPublished - 1979 Jan 1

    ASJC Scopus subject areas

    • Pharmacology (medical)
    • Infectious Diseases
    • Pharmacology
    • Drug Discovery
    • Oncology


    Dive into the research topics of 'Clinical studies on bacampicillin in the treatment of respiratory tract infections'. Together they form a unique fingerprint.

    Cite this